These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 11514604)

  • 1. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy.
    van Elsas A; Sutmuller RP; Hurwitz AA; Ziskin J; Villasenor J; Medema JP; Overwijk WW; Restifo NP; Melief CJ; Offringa R; Allison JP
    J Exp Med; 2001 Aug; 194(4):481-9. PubMed ID: 11514604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
    van Elsas A; Hurwitz AA; Allison JP
    J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.
    Sutmuller RP; van Duivenvoorde LM; van Elsas A; Schumacher TN; Wildenberg ME; Allison JP; Toes RE; Offringa R; Melief CJ
    J Exp Med; 2001 Sep; 194(6):823-32. PubMed ID: 11560997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors.
    Curran MA; Allison JP
    Cancer Res; 2009 Oct; 69(19):7747-55. PubMed ID: 19738077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Provision of granulocyte-macrophage colony-stimulating factor converts an autoimmune response to a self-antigen into an antitumor response.
    Ji Q; Gondek D; Hurwitz AA
    J Immunol; 2005 Aug; 175(3):1456-63. PubMed ID: 16034082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.
    Hurwitz AA; Yu TF; Leach DR; Allison JP
    Proc Natl Acad Sci U S A; 1998 Aug; 95(17):10067-71. PubMed ID: 9707601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.
    Hodi FS; Mihm MC; Soiffer RJ; Haluska FG; Butler M; Seiden MV; Davis T; Henry-Spires R; MacRae S; Willman A; Padera R; Jaklitsch MT; Shankar S; Chen TC; Korman A; Allison JP; Dranoff G
    Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4712-7. PubMed ID: 12682289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.
    Quezada SA; Peggs KS; Curran MA; Allison JP
    J Clin Invest; 2006 Jul; 116(7):1935-45. PubMed ID: 16778987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
    Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
    Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model.
    Espenschied J; Lamont J; Longmate J; Pendas S; Wang Z; Diamond DJ; Ellenhorn JD
    J Immunol; 2003 Mar; 170(6):3401-7. PubMed ID: 12626601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice.
    Mahnke K; Qian Y; Fondel S; Brueck J; Becker C; Enk AH
    Cancer Res; 2005 Aug; 65(15):7007-12. PubMed ID: 16061687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
    Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
    J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can regulate dendritic cell-induced activation and cytotoxicity of CD8(+) T cells independently of CD4(+) T cell help.
    McCoy KD; Hermans IF; Fraser JH; Le Gros G; Ronchese F
    J Exp Med; 1999 Apr; 189(7):1157-62. PubMed ID: 10190907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2.
    Tamada K; Harada M; Okamoto T; Takenoyama M; Ito O; Matsuzaki G; Nomoto K
    Cancer Immunol Immunother; 1995 Dec; 41(6):339-47. PubMed ID: 8635191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice.
    Liu Y; Peng Y; Mi M; Guevara-Patino J; Munn DH; Fu N; He Y
    J Immunol; 2009 May; 182(10):5960-9. PubMed ID: 19414747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.
    Saenger YM; Li Y; Chiou KC; Chan B; Rizzuto G; Terzulli SL; Merghoub T; Houghton AN; Wolchok JD
    Cancer Res; 2008 Dec; 68(23):9884-91. PubMed ID: 19047169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic T lymphocyte antigen-4 blockade enhances antitumor immunity by stimulating melanoma-specific T-cell motility.
    Pentcheva-Hoang T; Simpson TR; Montalvo-Ortiz W; Allison JP
    Cancer Immunol Res; 2014 Oct; 2(10):970-80. PubMed ID: 25038199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine.
    Chang EY; Chen CH; Ji H; Wang TL; Hung K; Lee BP; Huang AY; Kurman RJ; Pardoll DM; Wu T
    Int J Cancer; 2000 Jun; 86(5):725-30. PubMed ID: 10797297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.
    Curran MA; Montalvo W; Yagita H; Allison JP
    Proc Natl Acad Sci U S A; 2010 Mar; 107(9):4275-80. PubMed ID: 20160101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.